Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy.
Hervas-Stubbs S, Mancheño U, Riezu-Boj JI, Larraga A, Ochoa MC, Alignani D, Alfaro C, Morales-Kastresana A, Gonzalez I, Larrea E, Pircher H, Le Bon A, Lopez-Picazo JM, Martín-Algarra S, Prieto J, Melero I. Hervas-Stubbs S, et al. J Immunol. 2012 Oct 1;189(7):3299-310. doi: 10.4049/jimmunol.1102495. Epub 2012 Aug 27. J Immunol. 2012. PMID: 22925929
Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients.
Alfaro C, Perez-Gracia JL, Suarez N, Rodriguez J, Fernandez de Sanmamed M, Sangro B, Martin-Algarra S, Calvo A, Redrado M, Agliano A, Gonzalez A, Rodriguez I, Bolaños E, Hervás-Stubbs S, Perez-Calvo J, Benito A, Peñuelas I, Vigil C, Richter J, Martinez-Forero I, Melero I. Alfaro C, et al. J Immunol. 2011 Dec 1;187(11):6130-42. doi: 10.4049/jimmunol.1102209. Epub 2011 Nov 2. J Immunol. 2011. PMID: 22048768 Free article. Clinical Trial.
Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins.
Sanmamed MF, Carranza-Rua O, Alfaro C, Oñate C, Martín-Algarra S, Perez G, Landazuri SF, Gonzalez A, Gross S, Rodriguez I, Muñoz-Calleja C, Rodríguez-Ruiz M, Sangro B, López-Picazo JM, Rizzo M, Mazzolini G, Pascual JI, Andueza MP, Perez-Gracia JL, Melero I. Sanmamed MF, et al. Clin Cancer Res. 2014 Nov 15;20(22):5697-707. doi: 10.1158/1078-0432.CCR-13-3203. Epub 2014 Sep 15. Clin Cancer Res. 2014. PMID: 25224278
Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rγnull Immunodeficient Mice.
Sanmamed MF, Rodriguez I, Schalper KA, Oñate C, Azpilikueta A, Rodriguez-Ruiz ME, Morales-Kastresana A, Labiano S, Pérez-Gracia JL, Martín-Algarra S, Alfaro C, Mazzolini G, Sarno F, Hidalgo M, Korman AJ, Jure-Kunkel M, Melero I. Sanmamed MF, et al. Cancer Res. 2015 Sep 1;75(17):3466-78. doi: 10.1158/0008-5472.CAN-14-3510. Epub 2015 Jun 25. Cancer Res. 2015. PMID: 26113085
[Small-cell lung cancer].
Pérez-Gracia JL, López-Picazo JM, Martín-Algarra S, Viteri S, García-Foncillas J, Gúrpide A. Pérez-Gracia JL, et al. Rev Med Univ Navarra. 2007 Apr-Jun;51(2):7-13. Rev Med Univ Navarra. 2007. PMID: 17886708 Review. Spanish.
Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients.
Rodríguez-Ruiz ME, Perez-Gracia JL, Rodríguez I, Alfaro C, Oñate C, Pérez G, Gil-Bazo I, Benito A, Inogés S, López-Diaz de Cerio A, Ponz-Sarvise M, Resano L, Berraondo P, Barbés B, Martin-Algarra S, Gúrpide A, Sanmamed MF, de Andrea C, Salazar AM, Melero I. Rodríguez-Ruiz ME, et al. Ann Oncol. 2018 May 1;29(5):1312-1319. doi: 10.1093/annonc/mdy089. Ann Oncol. 2018. PMID: 29554212 Free article. Clinical Trial.
111 results